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Abstract
Objectives/purpose: To review Patient Reported Outcome (PRO) labelling claims achieved in oncology in Europe and in the United States 
and consider the benefits, and challenges faced.
Methods: PROLabels database was searched to identify oncology products with PRO labelling approved in Europe since 1995 or in the 
United States since 1998. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) websites and guid-
ance documents were reviewed. PUBMED was searched for articles on PRO claims in oncology.
Results: Among all oncology products approved, 22 were identified with PRO claims; 10 in the United States, 7 in Europe, and 5 in both. 
The language used in the labelling was limited to benefit (e.g. ￿￿resulted in symptom benefits by significantly prolonging time to deteriora-
tion in cough, dyspnoea, and pain, versus placebo￿) and equivalence (e.g. ￿no statistical differences were observed between treatment 
groups for global QoL￿). Seven products used a validated HRQoL tool; two used symptom tools; two used both; seven used single-item 
symptom measures (one was unknown). The following emerged as likely reasons for success: ensuring systematic PRO data collection; 
clear rationale for pre-specified endpoints; adequately powered trials to detect differences and clinically significant changes; adjusting for 
multiplicity; developing an a priori statistical analysis plan including primary and subgroup analyses, dealing with missing data, pooling 
multiple-site data; establishing clinical versus statistical significance; interpreting failure to detect change. End-stage patient drop-out rates 
and cessation of trials due to exceptional therapeutic benefit pose significant challenges to demonstrating treatment PRO improvement.
Conclusions: PRO labelling claims demonstrate treatment impact and the trade-off between efficacy and side effects ultimately facilitating 
product differentiation. Reliable and valid instruments specific to the desired language, claim, and target population are required. Practical 
considerations include rationale for study endpoints, transparency in assumptions, and attention to subtle variations in data.
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction 
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Background
Patient Reported Outcome (PRO) questionnaires are useful in assessing any aspect of patients￿ health status (disease and care) from 
their perspective [1]. They cover single and multi-dimensional concepts including, but not limited to, symptoms (e.g. nausea, dyspnoea), 
functioning, health-related quality of life (HRQoL), treatment satisfaction, and adherence [2]. Essentially, PROs provide an important per-
spective on how patients feel and function that cannot usually be adequately captured by clinical measures [3].
Although there are some evidence to suggest a relationship between tumour response and PRO data [4] traditionally, oncology clinical 
trial endpoints have focused on clinical measures such as tumour response rate and time to tumour progression (TTP) [5]. Nevertheless, 
improvement in long-term survival rates in some cancers, such as testicular [6] and recurrent breast cancer [7], have increased the need 
for long-term treatments for which impact upon patient symptoms and HRQoL is a key concern.
Recently, regulatory agencies, the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), emphasised the 
importance of PRO data and issued guidance on the incorporation of PRO instruments into clinical trials [1,8]. Including PRO endpoints in 
phase II and III clinical trials for oncology products can demonstrate treatment impact from the patient￿s perspective and make substantial 
contributions to the awareness of the disease burden on patients. PRO data can also provide significant prognostic information beyond 
standard clinical measure [9￿11].
Methods
The PROLabels database was searched to identify oncology products with PRO labelling which had been approved in Europe since 
1995 or in the United States since 1998. The FDA and EMA websites and guidance documents were reviewed. In addition, PUBMED was 
searched for relevant articles using the following keywords: ￿oncology￿ OR ￿cancer￿ AND ￿patient-reported outcomes￿ AND ￿claim￿, ￿label￿ 
or ￿regulatory￿.
Data were extrapolated from the Drug Product Label and the Summary Base Approval (SBA) (as available) including: the brand and generic 
product name, date of approval, label indication, type of PRO claim (e.g. HRQoL, symptoms, functioning), PRO claim language, PRO instru-
ments used, and PRO endpoint status. The PRO instruments used to obtain labelling claims were reviewed in light of FDA PRO guidance [12].
Results
PRO label claims granted in oncology products by FDA and EMA
A review of the PROLabels website (http://www.mapi-prolabels.org) revealed over 125 oncology products that were approved by FDA 
and/or EMA between 1995 and 2009. Of these, 22 were identified with PRO claims; 10 in the United States, 7 in Europe, and 5 in both 
(Table 1).
The majority of the label claims approved by both the FDA and EMA were based on signs and symptoms: six products obtained a label 
claim for pain, six products obtained a label claim for emesis and five products obtained a label claim for nausea. The language used in 
label claims was limited to showing benefit and equivalence (Table 2)
PRO questionnaires used to support label claims in oncology products
Looking at the label claims that have been granted after FDA draft guidance in 2006 (Table 3), a diverse range of instruments have been 
utilised to assess the impact of treatment upon patient symptoms and aspects of functioning, from single-item visual analogue scales to 
multidimensional questionnaires such as the Functional Assessment of Cancer Therapy￿Lung (FACT-L).www.ecancermedicalscience.com 3
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A review of the PROs used to obtain label claims in oncology products revealed that, in light of FDA guidance, they are generally not ￿fit 
for purpose￿ i.e. the majority of the instruments were developed without input from the intended treatment population.
Discussion
Challenges in obtaining PRO label claims in oncology
There are a number of potential challenges involved in achieving a PRO label claim for oncology products. First, the FDA guidance states 
￿Generally, findings measured by a well-defined and reliable PRO instrument in appropriately designed investigations can be used to 
Year
FDA EMA
All oncology 
approvals HRQoL
Signs and 
symptoms
Multiple 
labels
Any 
PRO￿
All 
oncology 
approvals HRQoL
Signs and 
symptoms
Multiple 
labels
Any 
PRO￿
Pre-draft guidance
 1995￿1996 2 1 ￿ 1 1   5
 1997￿1999 1 1 10 1   8
 2000￿2002 1 1 11 14
 2003￿2005 1 1 1 13 2 2 10
Post-draft guidance
 2006￿2008 1 1 19 23
 2009￿2010￿ 11  7 2 11  8
14
Total 2 7 3 2 60 4 10 4 68
￿Includes treatment satisfaction, use of rescue meds.
￿Until 31 September 2010.
Table 1: PRO label claims granted in oncology products by FDA and EMA, 1995￿2010
Benefit Equivalence
￿￿resulted in symptom benefits by significantly prolonging time to deterioration in cough, 
dyspnoea, and pain, versus placebo￿.
￿no statistical differences were observed between 
treatment groups for global QoL￿.
￿Quality of life outcomes differed according to EGFR mutation status. In EGFR mutation-
positive patients, significantly more IRESSA-treated patients experienced an improvement in 
quality of life and lung cancer symptoms vs carboplatin/paclitaxel￿.
￿
￿The mean sum of pain intensity differences at 30 minutes (SPID30) for ONSOLIS-treated 
episodes was statistically significantly higher than for placebo-treated episodes￿.
￿
Table 2: Language used in PRO label claimsecancer 2011, 5:212
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support a claim in medical product labelling if the claim is consistent with the instrument￿s documented measurement capabilities￿ [12]. 
This requires content validity to be established, including qualitative research, to ensure that items measure the intended concept, are 
relevant, comprehensive and understood by the intended population. PRO instruments should also be reliable, responsive, and able to 
detect change in the intended treatment population.
Table 3: PRO instruments used to support label claims, post 2006
Instrument Claim Regulatory agency Division
Signs and symptoms label claims
  VAS Pain EMA CDER ￿ Division of Gastroenterology 
Products Nausea EMA
Nausea FDA
 LCSS Symptoms EMA
  SPID30 Pain FDA CDER ￿ Division of Anesthesia, 
Analgesia, and Rheumatology Products
  Symptom Scale Assessment Symptom Palliation EMA
Health related quality of life label claims
 EORTC  QLQ-C30 HRQoL EMA
  FLIE Impact of chemotherapy-induced nausea and 
vomiting on patients￿ daily lives
FDA CDER ￿ Division of Gastroenterology 
Products
 FACT-L HRQoL EMA
VAS = 100 mm Visual Analogue Scale; LCSS = Lung Cancer Symptom Scale; SPID30 = Sum of pain intensity differences at 30 minutes; EORTC 
QLQ-C30 = EORTC Quality of Life Questionnaire (30 items); FLIE = Functional Living Index-Emesis; FACT-L = Functional Assessment of Cancer 
Therapy ￿ Lung; CDER = Center for Drug Evaluation and Research.
Figure 1: Common problems with classic PRO measurements.
Key
concepts
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Unclear
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Figure 1 shows further common problems with ￿classic￿ PRO instruments including inappropriate recall period and imprecise wording 
which can be problematic for patients to complete, therefore threatening the consistency and validity of data obtained.
Furthermore, there are specific challenges associated with oncology clinical trials, in particular the complexity of demonstrating symptom 
or HRQoL improvement in an indication where patients get progressively worse. Demonstrating long-term impacts of treatments requires 
the sample to be retained for the duration of the trial. This may be especially difficult in samples of late-stage and end-stage patients. In 
Pre-clinical
Consider the potential PRO benefits during draft TTP.
what you want to communicate, and how as a company
you want to position yourselves.
Develop an a priori statistical analysis plan including
primary and subgroup analyses.
Establish a sufficient sample size and adequately
powered trials to detect differences and clinically
significant changes, adjusting for multiplicity.
Ensure systematic PRO data collection and clear rationale
for pre-specified endpoints.
Consider how to deal with missing data, multiple
comparisons, and pooling multiple-site data.
Establish clinical versus statistical significance.
Interpret failure to detect change.
Preparation of value dossier for pricing and
reimbursement submissions.
Publish, communicate and disseminate information to
inform decisions on oncology treatments in clinical
practice.
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Figure 2: Strategic considerations across an anti-cancer product life-cycle.ecancer 2011, 5:212
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addition, oncology trials are often un-blinded which poses a problem for the accuracy of PRO data which is frequently subject to selection 
bias and reporting bias [13].
How to maximise chances for success in achieving a PRO label claim
The following may contribute towards obtaining an oncology PRO label claim:
•  ensuring systematic PRO data collection and clear rationale for pre-specified endpoints
•  establishing sufficient sample size and adequately powered trials to detect differences and clinically significant changes, adjust-
ing for multiplicity
• developing  an  a priori statistical analysis plan including primary and subgroup analyses
•  establishing ￿stringent￿ missing data criteria, adjusting for multiple comparisons, and being sensitive to pooling multiple-site 
data
•  establishing clinical versus statistical significance with clear a priori responder definitions
•  interpreting failure to detect change
These considerations should be taken at various points during the product life-cycle. Figure 2 provides an overview of when consideration 
of these factors during the product lifecycle is recommended. However, early planning to select, develop, and validate a PRO instrument 
is advisable in order to overcome these challenges and obtain a PRO label claim for an oncology product.
Study limitations and future recommendations
This review focussed on the use of PROs in clinical trials where a label claim has been granted. It is important to recognise the limitations 
that this presents. Due to availability of information in the public domain, it was not possible to assess oncology studies where PRO instru-
ments have been used inappropriately or unsuccessfully. Future research on a study-by-study basis would provide further insight into the 
successful use of PROs in oncology clinical trials.
This review indicates that PRO instruments can be used to demonstrate the impact of new treatments on symptoms, side effects, func-
tioning, and aspects of overall HRQoL. When incorporated into clinical trials PRO instruments can provide an important assessment of 
treatment benefit to patients. Further research with patients in disease-specific populations would be useful to investigate key concepts 
important to patients in order to identify appropriate PRO instruments.
Conclusions
PRO labelling claims demonstrate treatment impact, and the trade-off between efficacy and side effects ultimately facilitating product 
differentiation. Reliable and valid instruments specific to the desired language, claim, and target population are required. Practical consid-
erations include rationale for study endpoints, transparency in assumptions, and attention to subtle variations in data.
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